Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,027 Mln
P/E Ratio
--
P/B Ratio
3.45
Industry P/E
--
Debt to Equity
0.04
ROE
-0.76 %
ROCE
-74.47 %
Div. Yield
0 %
Book Value
3.36
EPS
-3.72
CFO
$-554.90 Mln
EBITDA
$-709.01 Mln
Net Profit
$-680.39 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals (SNDX)
| -1.59 | -5.11 | -7.07 | -37.93 | -7.47 | 3.23 | -- |
|
BSE Sensex*
| 2.03 | 3.81 | 4.34 | 8.27 | 11.76 | 20.17 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals (SNDX)
| -38.58 | -15.09 | 16.26 | -1.57 | 153.30 | 97.30 | -49.01 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R)... acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. Address: 730 Third Avenue, New York, NY, United States, 10017 Read more
CEO & Director
Mr. Michael A. Metzger M.B.A.
CEO & Director
Mr. Michael A. Metzger M.B.A.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Syndax Pharmaceuticals Inc (SNDX) stood at $ 725 Mln as on 31-Dec-24
The share price of Syndax Pharmaceuticals Inc (SNDX) is $13.01 (NASDAQ) as of 23-Apr-2025 16:15 EDT. Syndax Pharmaceuticals Inc (SNDX) has given a return of -7.47% in the last 3 years.
Syndax Pharmaceuticals Inc (SNDX) has a market capitalisation of $ 1,027 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Syndax Pharmaceuticals Inc (SNDX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Syndax Pharmaceuticals Inc (SNDX) and enter the required number of quantities and click on buy to purchase the shares of Syndax Pharmaceuticals Inc (SNDX).
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. Address: 730 Third Avenue, New York, NY, United States, 10017
The CEO & director of Mr. Michael A. Metzger M.B.A.. is Syndax Pharmaceuticals Inc (SNDX), and CFO & Sr. VP is Mr. Michael A. Metzger M.B.A..
There is no promoter pledging in Syndax Pharmaceuticals Inc (SNDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Syndax Pharmaceuticals Inc. (SNDX) | Ratios |
|---|---|
|
Return on equity(%)
|
-75.69
|
|
Operating margin(%)
|
-1325.29
|
|
Net Margin(%)
|
-1346.11
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Syndax Pharmaceuticals Inc (SNDX) was $0 Mln.
$0.09
(
